Literature DB >> 6827524

Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.

B S Iyengar, S M Sami, W A Remers, W T Bradner, J E Schurig.   

Abstract

A series of 7-(2-substituted-ethyl)amino analogues of mitomycin C and porfiromycin was prepared and screened in standard antitumor systems. Certain of these analogues showed better activity than mitomycin C against P-388 leukemia, L-1210 leukemia, and/or B-16 melanocarcinoma in mice. Compounds also tested for their leukopenic effects in mice, the limiting toxicity of mitomycin C. Some of them were less leukopenic and some were more leukopenic than this clinical agent. No statistically significant correlations could be made between physicochemical properties and antitumor activities of the analogues.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827524     DOI: 10.1021/jm00355a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).

Authors:  W T Bradner; W C Rose; J E Schurig; A P Florczyk
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

2.  Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.

Authors:  T Tsuruo; Y Sudo; N Asami; M Inaba; M Morimoto
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Disposition and metabolism of KW-2149, a novel anticancer agent.

Authors:  S Kobayashi; J Ushiki; K Takai; S Okumura; M Kono; M Kasai; K Gomi; M Morimoto; H Ueno; T Hirata
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Convergent synthesis of a steroidal antiestrogen-mitomycin C hybrid using "click" chemistry.

Authors:  Robert N Hanson; Edward Hua; David Labaree; Richard B Hochberg; Kyle Proffitt; John M Essigmann; Robert G Croy
Journal:  Org Biomol Chem       Date:  2012-09-25       Impact factor: 3.876

5.  Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Authors:  T Bando; K Kasahara; K Shibata; Y Numata; U Heki; H Shirasaki; K Iwasa; M Fujimura; T Matsuda
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.

Authors:  L Dirix; G Catimel; R Verdonk; E De Bruijn; B Tranchand; C Ardiet; A Van Oosterom
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.